M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Leukemia, Myelogenous, Chronic

Interventions: Drug: Nilotinib

First Posted Date: 2005-08-12

Last Posted Date: 2019-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 148

Registration Number: NCT00129740

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Phase 2

Withdrawn

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: Alemtuzumab (Campath-1H)

First Posted Date: 2005-08-12

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00129753

Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma

Not Applicable

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Curcumin
Drug: Bioperine

First Posted Date: 2005-06-13

Last Posted Date: 2011-11-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00113841

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma
Islet Cell Carcinoma

Interventions: Drug: RAD001
Drug: Octreotide Depot

First Posted Date: 2005-06-08

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 67

Registration Number: NCT00113360

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2005-06-08

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00113321

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Erlotinib
Drug: Docetaxel
Radiation: Radiation Therapy

First Posted Date: 2005-06-08

Last Posted Date: 2012-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00113347

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: ABT-510

First Posted Date: 2005-06-08

Last Posted Date: 2014-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00113334

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Avastin (Bevacizumab, RHUMAB VEGF)
Drug: Capecitabine
Radiation: Radiation Therapy

First Posted Date: 2005-06-07

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00113230

Locations: 🇺🇸
UT M. D. Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2005-06-07

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00113217

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Glioblastoma Multiforme

Interventions: Drug: Celecoxib
Drug: Isotretinoin
Drug: Temozolomide
Drug: Thalidomide

First Posted Date: 2005-06-03

Last Posted Date: 2021-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 178

Registration Number: NCT00112502

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy